Kornimate/medical-research-clean huggingface dataset:
symptom clusters and immune markers in patients with chronic obstructive pulmonary disease (copd) - a longitudinal study

Conditions: Chronic Obstructive Pulmonary Disease

Summary: copd patients often have a wide range of physical (e.g., dyspnea, fatigue, pain) and psychological (e.g., depression, anxiety) symptoms and various other debilitating conditions that cause considerable suffering for the individual. unfortunately, many of the symptoms and health problems in patients with copd are unrecognized and untreated. due to the irreversible nature of copd, the aim is not to cure the disease, but to reduce symptoms and improve quality of life. therefore, the purpose of this project is to investigate the existence and nature of symptom clusters over time in patients with copd and their effects on patient outcomes. since this study aims to identify possible new subgroups of patients with copd defined by the clustering of certain symptoms, the study also aims to investigate the relationship between the clinical presentation and certain immunologic and genetic factors.

the specific aims of this translational, interdisciplinary, multi-center, international research study will follow 308 copd patients with repeated measures over 12 months, are to: 1. explore copd patients' symptoms, symptom clusters, and changes in symptoms and symptom clusters over time; as well as the genetic markers for subgroups of patients with different symptom clusters. 2. identify the occurrence of hgg and assess immune function in copd patients. 3. explore relationships between hgg and immune function, genetic markers, symptoms, symptom clusters, health and respiratory status, frequency of exacerbations and health-related qol.

Eligibility criteria:
inclusion criteria: * degree 2-4 * above 18 years of age * able to read/ write/ speak norwegian exclusion criteria: * patients who are receiving treatment for cancer * acute exacerbations of copd

Keywords: symptoms dyspnea pain fatigue anxiety depression sleeplessness genetic markers immune markers copd quality of life
genome analysis across populations in inflammatory bowel disease

Conditions: Ulcerative Colitis; Healthy; Crohn Disease; Inflammatory Bowel Diseases

Summary: objective: to use clinical, genetic and genome analysis to better understand and define the genetic and environmental factors that contribute to ibd within affected populations.

background: inflammatory bowel disease (ibd) is a chronic, and often disabling, disorder of the intestines characterized by dysregulation of mucosal immune response. recent data suggests that the incidence and prevalence rates among all populations may be increasing due to constantly changing environmental exposures. the goal of the study is to identify susceptible genes that contribute to the pathogenesis of ibd in affected individuals.

Eligibility criteria:
inclusion criteria: * subjects: diagnosed with inflammatory bowel disease (crohn's disease, ulcerative colitis, ibd-undetermined) * available medical records to confirm ibd diagnosis (crohn's disease, ulcerative colitis, ibd undetermined (ibd-u)) * healthy controls: no personal history of ibd, no family history of ibd, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss * any age exclusion criteria: - subjects with other gastrointestinal conditions not meeting the above ibd or healthy control criteria
efficacy of terlipressin therapy in acute variceal haemorrhage after evl

Conditions: Acute Variceal Haemorrhage

Summary: upper gastrointestinal (ugi) bleed of variceal origin is a common medical emergency. prompt endoscopic variceal ligation (evl) is therapeutic as well as diagnostic. terlipressin, a vasopressin analog (intravenous, 2 mg q 4 hourly), is widely used promptly in any suspicious case of variceal haemorrhage (vh) before endoscopic procedure, along with volume and blood resuscitative measures. as per guideline, after evl terlipressin therapy (1 mg iv q 4 hourly) is continued for 2-5 day to prevent re-bleed. but the prolong use of terlipressin is not completely safe as well as it is expensive also in resource constraint setting. at present there is no clinical trial available to prove the efficacy of post-evl terlipressin therapy in preventing re-bleed and mortality in cases of acute variceal haemorrhage. during the post marketing surveillance terlipressin therapy has been found to be associated with life threatening complication like cardiac arrhythmia, myocardial ischemia, critical vasoconstriction of peripheral as well as internal organ leading to ischemia or gangrene, severe hyponatremia, hypertension, fluid overload and pulmonary oedema. so the justification of continuing terlipressin therapy for 5 days after evl is questionable, as haemostasis is primarily achieved by evl and the risk versus benefit of terlipressin therapy after evl is still unknown. continue iv terlipressin therapy also prolongs in-hospital care causing further increase of health care burden. there is still lack of data of terlipressin therapy, regarding its efficacy in preventing post-evl re-bleed, mortality, adverse drug events and cost effectiveness. the investigator will study to evaluate the utility of terlipressin therapy after evl, in acute variceal haemorrhage.


Eligibility criteria:
inclusion criteria: * irrespective of gender with age ≥ 18 years * all the patients with endoscopy proven acute variceal haemorrhage (vh) * receiving pre-evl terlipressin therapy * evl done within 24 hours of presentation * ready to give written informed consent exclusion criteria: * patients with ugi bleed for more than 24 hours * not receiving pre-evl terlipressin therapy * pregnancy * past history of evl * chronic kidney disease * patient's with evl done beyond 24 hours of admission because of hemodynamic instability or encephalopathy * patients who are receiving blood thinners like anti-platelets, anti-coagulation agents within 4 weeks of presentation

Keywords: terlipressin, variceal haemorrhage, evl
result of use of wide awake local anaesthesia in fixation of ankle fractures

Conditions: Local Anesthesia

Summary: to assess the success of wide-awake local anaesthesia in fixation of ankle fractures

the wide-awake local anesthesia with no tourniquet provides an alternative method for the existing anesthesia methods including general anesthesia, intrathecal, epidural anesthesia, peripheral nerve block and local anesthesia with intravenous sedation. each method of them has its inherent risks and costs. the wide-awake local anesthesia has few risks for the patient and can be used in satisfaction where other types of anesthesia particularly general anesthesia are contraindicated. this method is safe, effective and provides satisfactory pain and anxiety scores. patients don't have to stay for a long time after surgery. it allows the surgery to be done without tourniquet due to the use of epinephrine and this avoids the complication of tourniquet and allows the surgery to be done safely in cases of limb vascular insufficiency and in diabetic patients where tourniquet usage is not favorable. wide awake local anesthesia method for ankle fracture management is not a novel idea; it was previously investigated in one study but the limitation of this study that it was retrospective study with small sample size and without control group treated with other anesthetic modalities. there is concern that the use of lidocaine in hematoma block is harmful for joint cartilage. excess use of epinephrine may cause excessive vasoconstriction and cyanosis of fingers . neuropathic complication are notably high during the early postsurgical period . wide-awake anesthesia is delivered by the surgeon . the role of anesthetic team, if needed, is monitoring the vital signs and in case of failure of wide-awake and prolonged time of surgery .

Eligibility criteria:
inclusion criteria: * all adult patients with unstable ankle fracture who need fixation presenting to the trauma unit of assiut university hospital with the following criteria: 1. age ≥ 18 years. 2. isolated ankle fracture in one or both lower limbs. exclusion criteria: 1. patients\< 18 years. 2. patients with uncontrolled diabetes mellitus. 3. open fractures. 4. associated fractures in the lower limbs(spinal anaesthesia will be more suitable in multiple fractures) 5. fractures managed by closed contact casting. 6. patients with dementia and psychological disease.

Keywords: wide_awake
health benefits of chronic vs. acute exercise in overweight adults

Conditions: Obesity

Summary: compare the effects of single session of exercise vs. chronic exercise training on key risk factors associated with metabolic syndrome (e.g., glucose tolerance, blood lipid profile, and blood pressure) in overweight adults.


Eligibility criteria:
inclusion criteria: * body mass index: 27-34 kg/m2; * regular exercisers(≥4 days/wk of aerobic exercise; * 30-60min/session at moderate and vigorous intensities); * non-exercisers (no regularly planned exercise/physical activity); * women must have regularly occurring menses and must be premenopausal. exclusion criteria: * pregnant or lactating; * evidence/history of cardiovascular or metabolic disease; * currently taking medications known to affect lipid or glucose metabolism.

Keywords: insulin sensitivity exercise
the effect of therapeutic touch on sleep patterns

Conditions: Therapeutic Adherence; Nurse-Patient Relations; Sleep Disorder

Summary: the aim of this study is to determine the effect of the therapeutic touch applied to the sleep patterns of individuals aged 65-85 years with chronic diseases who are treated in the neurology intensive care unit of ankara city hospital, taking into account the circadian cycle.the type of the research is the experimental model with pre-test and post-test control group.ankara city hospital has included the research population in the last year. it will consist of 1593 patients between the ages of 65-85 who are hospitalized in the neurology intensive care unit.experimental and control groups will be created with simple randomization in randomization.the data were obtained from the socio-demographic characteristics form and the sleep pattern form developed by the researcher. will be collected with

the aim of this study is to determine the effect of the therapeutic touch applied to the sleep patterns of individuals aged 65-85 years with chronic diseases who are treated in the neurology intensive care unit of ankara city hospital, taking into account the circadian cycle.research hospitalization in ankara city hospital neurology intensive care it will be done with individuals who have chronic diseases in the 65-85 age range. research it is planned to be held between november 2021 and december 2022.therapeutic touch will be applied to the patients selected in the experimental and control groups among the patients who meet the research criteria in the intensive care units. after this application, the sleep pattern changes in the patients will be evaluated.therapeutic touch will be applied to the patients selected in the experimental and control groups among the patients who meet the research criteria in the intensive care units. after this application, sleep pattern changes in patients will be evaluated. in the analysis of the research, dependent groups t test andindependent groups t test, mann whitney u and kruskal wallis tests will be used in non-parametric cases

Eligibility criteria:
inclusion criteria: * being in the age range of 1.65-85 years * having a chronic disease * the patient's hospitalization in the neurology intensive care unit exclusion criteria: * not in the age range of 65-85 years * not being able to communicate (being intubated, having hearing impairment, etc.)
effectiveness of doll therapy in people with dementia

Conditions: Dementia

Summary: this study aims to evaluate the effectiveness of doll therapy in reducing the daily dose of medications (ddm), behavioral and psychological symptoms of dementia (bpsd), and improving the activities of daily living (adl) in people living with dementia (plwd) in residential care facilities in china. the study employs a cluster randomized controlled trial design, involving 142 participants from six nursing homes, divided into an intervention group receiving doll therapy plus routine nursing care and a control group receiving routine nursing care alone. additionally, the study will explore the experiences and perceptions of staff and family caregivers through qualitative research methods to provide a comprehensive understanding of the intervention's impact.

doll therapy, recognized as a non-pharmacological intervention, involves providing lifelike baby dolls to individuals with dementia to elicit positive emotional responses and behaviors. despite its potential benefits, evidence supporting its efficacy and acceptability remains limited and inconclusive. this mixed-method research study will conduct a cluster randomized controlled trial to systematically evaluate the effectiveness of doll therapy in reducing the daily dose of medications, mitigating behavioral and psychological symptoms, and enhancing daily living activities among chinese dementia patients in residential care settings. the trial will involve 142 participants from six nursing homes, randomly assigned to either the intervention group (doll therapy plus routine care) or the control group (routine care only). quantitative outcomes will be measured using standardized scales for medication use, bpsd, and adl. in parallel, qualitative data will be collected through interviews with staff and family caregivers to gain insights into their experiences and perceptions of doll therapy. the findings are anticipated to inform best practice guidelines for implementing doll therapy in dementia care.

Eligibility criteria:
inclusion criteria: * participants must be at least 65 years old. * documented diagnosis of dementia. * sufficient manual dexterity to hold or caress a doll. * sufficient visual acuity to recognize a doll. * must have legal family members or next of kin to sign the consent form. exclusion criteria: * individuals with mild dementia who do not accept the doll after two attempts. * participants who accept the doll but leave it within two weeks. * individuals without the capacity to give informed consent and without a legal representative to provide consent on their behalf.
repeat emergency department visits among patients with asthma and copd

Conditions: Asthma; COPD

Summary: the purpose of the proposed study is to determine whether the addition of inhaled corticosteroids to treatment with oral corticosteroids and albuterol would reduce repeat emergency department (ed) visits among patients treated for acute exacerbations of asthma and copd discharged from the emergency department to home. the investigators hypothesize that patients treated with inhaled corticosteroids in addition to oral corticosteroids and albuterol will have lower rates of 30-day return visits to the emergency department than those patients treated with oral corticosteroids and albuterol only.


Eligibility criteria:
inclusion criteria: * treated in the ed at the erie county medical center (ecmc) for acute symptoms of asthma or copd during the study period * patient age ≥ 18 years * resident of the city of buffalo or erie county * discharged to home * patient expresses willingness to return to ecmc or own primary care provider for follow-up visits * able to provide informed consent * able to comprehend english language exclusion criteria: * received oral or inhaled corticosteroids in the week before ed presentation * presented to the ed primarily for prescription refills * complicated comorbid conditions (e.g. renal disease, cardiovascular disease, chf, hiv) * admitted to ecmc or discharged to another facility * previously enrolled during a prior visit to the ed during the study period * for female patients--pregnant or pregnancy status indeterminate * antibiotics are prescribed to treat current asthma/copd exacerbation.
extended follow-up study for subjects who participated in 2010 study

Conditions: Body Fat Disorder

Summary: this study is being performed to follow up on subjects who participated in the initial study (za10-001) in 2010.

the primary objective of this investigation is to assess the durability of treatment outcomes with the zeltiq system.

Eligibility criteria:
inclusion criteria: 1. subject participated in the za10-001 study, and received all study treatments. 2. subject has read and signed a written informed consent form. exclusion criteria: 1. subject has had any surgical or aesthetic procedure(s) in or around the abdomen since the completion of the za10-001 study treatments. 2. subject is pregnant. 3. subject is unable or unwilling to comply with the study requirements. 4. subject is currently enrolled in a clinical study of any other unapproved investigational drug or device. 5. any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the integrity of the data.

Keywords: lipolysis cryolipolysis fat reduction
evaluating the effect of inositol supplementation in overweight children on basal insulin and body weight

Conditions: Insulin Resistance

Summary: inositol in involved in the insulin pathway. in literature it has been demonstrated to improve insulin sensitivity and ovarian function in women affected by pcos. in a preliminary study conducted on obese children between 7 and 15 years, the investigators have demonstrated that inositol administration (myo-inositol 1100 mg + d-chiro-inositol 27,6 mg + folic acid 400 μg) before a glucose oral tolerance test reduces the increase of insulin levels, particularly in subjects with basal insulin ≥ 15 uu/ml. so the aim of this study is to evaluate the potential therapeutic effect of inositol, as non-pharmacologic agent, in preventing tipe ii diabetes in children.


Eligibility criteria:
inclusion criteria: * 8-18 years old * overweight or obesity * basal insulin ≥ 20 uu/ml exclusion criteria: * pubertal delay * hypogonadism * hypothyroidism or hyperthyroidism * obesity-related genetic diseases

Keywords: inositol insulin resistance overweight children
attaining and maintaining wellness in obsessive-compulsive disorder

Conditions: Obsessive Compulsive Disorder

Summary: the goal of this study is to understand whether patients with obsessive-compulsive disorder (ocd) on serotonin reuptake inhibitors (sris) who receive a type of cognitive-behavioral therapy called exposure and ritual prevention (ex/rp) can discontinue their medication if they first do well with ex/rp.

this study begins with a preparatory phase, wherein all eligible participants receive up to 25 sessions of exposure and ritual prevention (ex/rp) therapy. at the end of the preparatory phase, those who have achieved wellness (mild to minimal symptoms) enter the study phase. those who do not achieve wellness will not continue in the study and are referred for treatment elsewhere. those who enter the study phase are then assigned by chance to one of two groups. one group will continue on the sri medication and the other group will discontinue the sri gradually over 4-6 weeks as it is replaced with a placebo (sugar pill). neither patients nor study staff will know which group a participant is in. both groups will continue to receive monthly sessions of ex/rp. the study will examine who has the best response to treatment in this study, including taking blood samples for genetic testing to see whether there are genes that can predict who will or will not benefit from ex/rp.

Eligibility criteria:
preparatory phase inclusion criteria: * primary diagnosis of ocd * currently on a stable and adequate dose of a serotonin reuptake inhibitor (i.e., clomipramine, fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, escitalopram) but still have clinically significant ocd symptoms exclusion criteria: * comorbid psychiatric conditions that significantly elevate the risks of study participation (e.g. psychotic disorders, bipolar disorder, evidence of dementia or other cognitive disorder, suicidality) * unstable medical conditions that need attention and would make participation in the study unsafe (e.g., very high blood pressure) * patients who have already had prior adjunctive ex/rp (more than 8 sessions within 2 months) while receiving an adequate sri trial * patients taking other medications besides an sri (e.g. antipsychotics, mood stabilizers, other antidepressants besides sris) * patients who are pregnant, sexually active and not using contraception, or nursing study phase inclusion criteria: * those who achieve mild to minimum ocd symptoms from preparatory phase will enter the study phase exclusion criteria: * all exclusions listed above for preparatory phase are exclusions for study phase as well * patients who are depressed at the end of the preparatory phase are excluded from study phase
nocturnal oxygenation and sleep-related breathing disorders during the first night of a stay at 2500m of high altitude in patients with precapillary pulmonary hypertension

Conditions: High Altitude Pulmonary Hypertension; Sleep

Summary: the impact of hypoxia at 2500m of high altitude on sleep in patients with precapillary pulmonary hypertension


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature (appendix informed consent form) * ph class i (pah) or iv (cteph) diagnosed according to guidelines: mean pulmonary artery pressure \>20 mmhg, pulmonary vascular resistance ≥3 wood units, pulmonary arterial wedge pressure ≤15 mmhg during baseline measures at the diagnostic right-heart catheterization exclusion criteria: * resting partial pressure of oxygen \<8 kilopascal at zurich at 490 m low altitude * exposure to an altitude \>1000 m for ≥3 nights during the last 2 weeks before the study * inability to follow the procedures of the study * other clinically significant concomitant end-stage disease (e.g., renal failure, hepatic dysfunction)
the assessment of a weight-gain agent for the treatment of olanzapine-associated anti-obesity agent in patients with schizophrenia, schizophreniform disorder, schizoaffective disorder, and bipolar i disorder

Conditions: Schizophrenia; Psychotic Disorders; Bipolar Disorder

Summary: olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. this anti-obesity agent is currently marketed for the management of obesity. in this study, the anti-obesity agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine. the purposes of this study are to determine the safety of olanzapine when given in combination with the anti-obesity agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine.


Eligibility criteria:
eligibility criteria: * you must be between the ages of 18 and 65. if you have reached your 66th birthday, you will not be able to participate. * you must have been diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar i disorder and be taking olanzapine. * you must be able to visit the doctor's office as scheduled for the next 4 months. exclusion criteria: * you have a history of an illness that would cause weight loss or gain in the near future. * you have taken remoxipride within the past 6 months. * you are allergic to olanzapine or anti-obesity agent. * you have uncontrolled high blood pressure, congestive heart failure, or have had a stroke. * you have a serious medical illness, such as heart, liver, or kidney disease. * you are pregnant or breast feeding.

Keywords: schizoaffective disorder schizophreniform disorder bipolar i disorder